Tuberculosis then and now: A personal perspective on the last 50 years

Annals of Internal Medicine

Volumn 126, Issue 3, 1997, Pages 237-243

  Snider, Gordon L ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ISONIAZID; STREPTOMYCIN;

FINANCIAL MANAGEMENT; HOMELESSNESS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRATION; MORTALITY; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SOCIOECONOMICS; TUBERCULOSIS; UNITED STATES;

EID: 0031039119     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-3-199702010-00011     Document Type: Review

References (35)

1. Pinner M. Pulmonary Tuberculosis in the Adult: Its Fundamental Aspects. Springfield, IL: C.C. Thomas; 1945.
2. Statistical Compendium on Adult Lung Disease. American Lung Association, Epidemiology and Statistics Unit, Division of Medical Affairs; 1987.
3. Schulte D. Lung Disease Data 1994. New York: American Lung Assoc; 1994:37.
4. Lowed A, Edwards L, Palmer C. Tuberculosis. Cambridge, MA: Harvard Univ Pr; 1969:34, 46, 68.
5. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1994. July 1995:5.
6. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, Sanchez MA, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med. 1995;1:815-21.
7. American Hospital Association. Hospital Statistics 1968-1993. Chicago: American Hospital Association.
8. Rothman SM. Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History. New York: Basic Books; 1994.
9. Taylor R. Saranac: America's Magic Mountain. Boston: Houghton Mifflin; 1986.
10. Wells WF. On airborne infection, II: droplets and droplet nuclei. Am J Hyg. 1934;20:611-8.
11. Kayne GG, Pagel W, O'Shaughnessy LF. Kayne, Pagel, and O'Shaughnessey's Pulmonary Tuberculosis: Pathology, Diagnosis, Management and Prevention. London: Oxford Univ Pr; 1948.
12. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med. 1944;55:66-9.
13. Lehmann J. Para-ammosahcylic acid in the treatment of tuberculosis. Lancet. 1946;1:15-6.
14. Barnwell JB. Veterans Administration Tuberculosis Division 1945-1947. American Review of Tuberculosis. 1948;58:64-76.
15. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948;2:769-82.
16. Lilienfeld AH. The Fielding M. Garrison Lecture. Ceterus paribus: the evolution of the clinical trial. Bull Hist Med. 1982;56:1-18.
17. Robitzek EH, Selikoff IJ. Hydraztne derivatives of isonicotinic acid (Rimifon, Marsalid) in the treatment of active progressive caseous-pneumonic tuberculosis. A preliminary report. Am Rev Tuberc. 1952;65:402-28.
18. Ryan F. The Forgotten Plague: How the Battle against Tuberculosis Was Won - and Lost, Boston: Little, Brown; 1992.
19. Moodie AS. Ambulatory treatment of tuberculosis in Hong Kong. Tubercle. 1956;37:451-4.
20. Tuberculosis Chemotherapy Center Madras. A concurrent comparison of home and sanitorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1959;21:51-144.
21. D'Esopo ND. Clinical trials in pulmonary tuberculosis. Am Rev Respir Dis. 1982;125:85-93.
22. Murray G. Issues in operational, social, and economic research in tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM Pr; 1994:583-622.
23. Long ER. Recommendations of the Arden House Conference on Tuberculosis. Am Rev Respir Dis. 1960;81:481-4.
24. Moulding T, Dutt AK, Relchman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med. 1995;122:951-4.
25. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328:521-6.
26. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis, We can't afford not to try it. N Engl J Med. 1993;328:576-8.
27. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-84.
28. Schluger N, Clotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med. 1995;151:1486-90.
29. Tuberculosis morbidity-United States, 1995. MMWR Morb Mortal Wkly Rep. 1996;45:365-9.
30. Snider DE, Onorato IM. Epidemiology. In: Rossman MD, MacGregor RR, eds. Tuberculosis: Clinical Management and New Challenges. New York: McGraw-Hill; 1995:3-17.
31. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization [Editorial]. Tubercle. 1991;72:1-6.
32. Snider DE. Tuberculosis: the world situation. History of the disease and efforts to combat it. In: Porter JD, McAdam KP, eds. Tuberculosis: Back to the Future. New York: J Wiley; 1994:13-33.
33. Sontag S. Illness as Metaphor and Aids and its Metaphors. New York: Anchor Books; 1990.
34. Dubos RJ, Dubos J. The White Plague: Tuberculosis, Man and Society. Boston: Little, Brown; 1952.
35. Young DB. Strategies for new drug development. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection and Control. Washington, D.C.: ASM Pr; 1994:559-67.